• Novartis v. Eli Lilly (N.D. Cal., E.D. Va., 4th Cir., 9th Cir., and ex-U.S.). Represented Eli Lilly & Co. in global litigations, serving as U.S. counsel in 28 U.S.C. § 1782 discovery actions for use in foreign proceedings, and strategic co-counsel in multiple European litigations and European Patent Office proceedings that arose from the sale of a patent portfolio from Genentech, Inc. to Novartis Pharma AG. In October 2022, Novartis and Lilly entered into a global settlement agreement that concluded the dispute between the parties.
    • Par Pharmaceutical, Inc. v. Amneal EU Ltd., et al. (D. Del.). Trial counsel representing Par in a Hatch-Waxman patent infringement case regarding Par’s Vasostrict® product against multiple generic pharmaceutical manufacturers. 
    • Cedars-Sinai Medical Center v. Quest Diagnostics, Inc. (C.D. Cal.).  Served as lead counsel for Defendant Quest Diagnostics accused of patent infringement, trade secret misappropriation, and breach of contract.  Obtained summary judgment of invalidity and jury verdict of no misappropriation or breach.
    • Endo Pharmaceuticals Inc. vs. Teva Pharmaceuticals USA, Inc., et al. (D. Del.). Trial counsel representing Endo in a Hatch-Waxman patent infringement case regarding Endo's OPANA® ER controlled release oxymorphone product against seven generic pharmaceutical manufacturers. Obtained verdict of infringement and validity. 
    • Endo Pharmaceuticals Inc. vs. Teva Pharmaceuticals USA, Inc., et al. (S.D.N.Y.). Trial counsel representing Endo in a Hatch-Waxman patent infringement case regarding Endo's OPANA® ER controlled-release oxymorphone product against seven generic pharmaceutical manufacturers. Obtained verdict of infringement and validity. 
    • Endo Pharmaceuticals Inc. vs. Watson Pharmaceuticals, Inc., et al. (S.D.N.Y.). Trial counsel representing Endo in a Hatch-Waxman patent infringement case regarding Endo's Lidoderm® lidocaine patch product against generic pharmaceutical manufacturers. Settled favorably after trial.
    • Amgen Inc. v. F. Hoffman LaRoche, Ltd. (D. Mass.). Served as a member of the Senior Trial Team representing Amgen in a patent infringement case regarding recombinant erythropoietin. Obtained a jury verdict of infringement and validity.
    • In the Matter of Certain Products and Pharmaceutical Compositions Containing Recombinant Human Erythropoietin (USITC). Trial counsel for Amgen in ITC investigation regarding the exclusion from importation into the U.S. of Roche's Mircera® product (appeal in Amgen's favor, settled favorably).
    • Pfizer Inc v. Lilly ICOS (D. Del.). Defended Lilly ICOS in a patent dispute regarding phosphodiesterase-5 inhibitors Cialis® and Viagra®. Obtained stay after successful petition for reexamination.
    • Boston Scientific v. Cook (C.D. Ill. and 7th Cir.). Counsel for Angiotech in dispute between licensees regarding license rights to paclitaxel stents (favorably resolved).
    • Amgen Inc. v. Hoechst Marion Roussel, Inc. (D. Mass.). Represented Amgen in this patent dispute, obtaining holdings of infringement and validity in two bench trials as well as numerous appeals.
    • Biogen v. Amgen (D. Mass.). Represented Amgen in infringement action involving Amgen's recombinant granulocyte colony stimulating factor product (Neupogen®) (summary judgment in Amgen's favor).